The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Sep. 1, 3:28 AM

Slide #22. Insmed Incorporated Secondary Offering

Company: Insmed Incorporated (NASDAQ:INSM)
Date announced: 8/11/2014
Shares Offered: 8,900,000
Date of Pricing: 8/12/2014
Price Per Share: $11.25
Secondary Offering Details: Insmed Incorporated (NASDAQ:INSM) announced today that it has commenced an underwritten public offering of $80 million of its common stock. All of the shares of common stock in the offering are to be sold by Insmed. - updated 8/13 - Insmed Incorporated (NASDAQ:INSM) announced today that it priced an offering of 8.9 million shares of its common stock at a price of $11.25 per share in a registered underwritten public offering for gross proceeds totaling approximately $100 million. All of the shares in the offering are being sold by Insmed. Net proceeds to Insmed from this offering are expected to be approximately $94 million, after deducting underwriting discounts and commissions, and other estimated offering expenses payable by Insmed. The offering is expected to close on or about August 18, 2014, subject to the satisfaction of customary closing conditions.

Insmed develops and commercializes inhaled therapies for patients with lung diseases. Co.'s main product candidate, ARIKAYCE® (liposomal amikacin for inhalation), is an inhaled antibiotic treatment for lung infections. Co. is conducting a phase two clinical trial of ARIKAYCE in patients who have lung infections caused by non-tuberculous mycobacteria, and a two-year, open label safety study in patients that also completed its phase three clinical study of ARIKAYCE for cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pseudomonas) lung infections. Co. is also developing ARIKAYCE for Pseudomonas and other susceptible organisms causing lung infections in non-CF bronchiectasis patients.
Open the INSM Page at The Online Investor »

Company Name:  Insmed Inc
Sector:  Biotechnology
Number of ETFs Holding INSM:  14
Total Market Value Held by ETFs:  $29.35M
Total Market Capitalization:  $548.00M
% of Market Cap. Held by ETFs:  5.36%

Open the INSM Page at The Online Investor (in a new window) »

September 1, 2014    3:28 AM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
96th percentile
(ranked higher than approx. 96% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.